Formula I Anticancer Conjugates With Lower Normal-Cell Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-cancer compounds are often toxic to normal cells and ineffective at tolerable doses, necessitating the development of new compounds with improved efficacy and reduced toxicity for treating various cancers.
Innovation Solution
Development of compounds of Formula (I) and their derivatives, which can be administered in specific doses and forms to target cancer cells while minimizing harm to normal cells, including pharmaceutical compositions and methods for their preparation and administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-cancer compounds are administered at effective doses, then tumor growth inhibition is achieved, but toxicity to normal cells increases
Solution Approach 1:
The patent applies local quality by creating compounds with specific molecular structures (Formula I) that have differentiated interaction properties - they bind preferentially to cancer cell targets while having reduced affinity for normal cell targets. This is achieved through specific substituent patterns (R1-R7 groups) that confer selective recognition, allowing the same compound to have different effective concentrations for cancer versus normal cells.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations in Formula I) to optimize the therapeutic window. By adjusting these structural parameters, the compounds achieve enhanced potency against cancer cells while simultaneously reducing toxicity to normal cells, effectively changing the dose-response parameters for different cell types.
2Object-affected harmful factors
If the dose of anti-cancer compounds is reduced to minimize toxicity, then safety improves, but anti-cancer efficacy decreases
Solution Approach 1:
The compounds exhibit local quality through their molecular structure (Formula I) that creates asymmetric interaction with different cell types. The specific arrangement of R1-R7 substituents provides localized binding characteristics that allow high affinity for cancer cell targets at low concentrations, while showing low affinity for normal cell targets even at higher concentrations, thus decoupling the dose requirements for efficacy versus toxicity.
Solution Approach 2:
The patent utilizes parameter changes by optimizing molecular parameters in Formula I to achieve a shifted dose-response curve. The compounds demonstrate enhanced potency (lower ED50 for cancer cells) and reduced toxicity (higher LD50 for normal cells), effectively changing the dosage parameters to expand the therapeutic window where safe dosing achieves maximum anti-cancer effect.
3Reliability
If new compounds with improved selectivity are developed, then therapeutic index improves, but development complexity increases
Solution Approach 1:
The patent applies universality by designing a platform compound (Formula I) with multiple substitutable positions (R1-R7) that can accommodate various functional groups. This universal scaffold can be systematically modified to target different cancer types or overcome various resistance mechanisms while maintaining the core selective binding pharmacophore, allowing one base structure to serve multiple therapeutic purposes through rational substituent selection.
Data Source
AI summary
Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g. pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating. Further embodiments include methods for making the inventive compound. Additional embodiments of the invention are also discussed herein.